India's Bioeconomy Reaches $190 Billion After 20-Fold Growth Over 12 Years

A 20-fold expansion in India's bioeconomy over 12 years signals a structural shift in the country's contract manufacturing capacity, biosimilar pipeline depth, and regulatory infrastructure, developments that carry direct implications for global pharma supply chain strategy. Union Minister Dr Jitendra Singh confirmed the milestone at a recent government briefing, placing India's bioeconomy at over $190 billion, up from approximately $10 billion a decade ago.

The growth is not limited to headline figures. India has developed an indigenous CAR-T cell therapy, a modality that demands stringent sterility assurance, validated cold-chain logistics, and advanced GMP-compliant manufacturing environments. For plant heads and QA directors evaluating India-based CDMOs or biosimilar partners, this signals a meaningful upgrade in technical capability across at least a segment of the domestic manufacturing base.

The startup ecosystem has expanded in parallel, with biotechnology ventures increasingly operating within frameworks aligned to ICH Q10 pharmaceutical quality systems and international regulatory expectations. That alignment matters for global sponsors conducting supplier qualification audits or preparing for multi-regional submissions where Indian manufacturing sites appear in the dossier.

Regulatory infrastructure has not kept pace uniformly. The Central Drugs Standard Control Organisation (CDSCO) continues to work through harmonisation with 21 CFR Part 211 and EMA GMP expectations, and inspection backlogs remain a practical concern for sponsors relying on Indian API or finished-dose sites for regulated-market supply. The bioeconomy growth narrative is real, but due diligence on site-specific compliance history remains non-negotiable.

For regulatory affairs leads, the CAR-T development is a useful reference point: indigenous advanced therapy manufacturing in India now exists, which affects how global firms model regional supply redundancy and technology transfer feasibility for complex biologics.

The $190 billion figure will likely anchor India's positioning in upcoming bilateral trade and pharma partnership negotiations, making it a number that supply chain and regulatory teams should expect to encounter in government-to-government and CDMO commercial discussions through the remainder of 2026.

Source: Indian Pharma Post via Media4Growth, 15 June 2026.